Nabla's Distribution Unlocks AMI Integration
AMI Labs
The real asset in this partnership is distribution inside hospital software and compliance workflows, not just model quality. In healthcare, getting into a live clinician workflow usually means passing security review, signing business associate agreements, integrating with the EHR, and winning approval from health system leadership. Nabla already sits inside that path with deployment across more than 150 health systems and provider groups, which gives AMI a way to test and refine healthcare use cases in production settings instead of starting from zero.
-
AI scribes are a useful wedge because they already capture the raw material for broader clinical automation. Nabla listens to the visit, generates the note, and increasingly plugs into coding and other follow on tasks. That means an AMI layer could sit underneath a workflow that already touches clinician conversation, patient history, and structured EHR fields.
-
The hard part in healthcare is not just selling a doctor a tool, it is going deep enough into the EHR to remove real work. Research on the scribe market shows larger health systems choose vendors based on integration depth and enterprise readiness, while HIPAA and business associate agreements push products into top down sales. Partnering with Nabla lets AMI borrow that enterprise access.
-
Comparable companies show why this matters. Abridge scaled to 60,000 plus clinicians across 100 plus health systems after partnering with Epic and Athenahealth, and its edge came from deeper integration, not simply a better note generator. Nabla is smaller in market power than Abridge, but the same logic applies, distribution compounds model advantage in clinical software.
From here, the partnership can move AMI from healthcare research into healthcare infrastructure. If Nabla keeps expanding from ambient documentation into coding, orders, and broader care workflows, AMI gains a growing surface area where deterministic world models can shape real decisions, creating a path from assistant features toward safety critical clinical agents.